Adstiladrin received FDA approval on December 16, 2022. It represents a significant advancement in cancer therapy, particularly for patients who have not responded to standard treatments.
Jul 26th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
IASO Biotechnology announced that the FDA has approved its application for a new drug, Equecabtagene Autoleucel (Eque-cel), a fully human anti-BCMA CAR T cell therapy.
Enterprise Therapeutics has today revealed that the first participant with cystic fibrosis has been administered a dose in its Phase 2a study of ETD001.